



Attorney Docket No.: A-63096/RFT/JJD  
(Genentech Ref. P993)

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bruce A. KEYT, *et al.*

Serial No.: 08/734,443

Filed: October 17, 1996

For: VARIANTS OF VASCULAR  
ENDOTHELIAL GROWTH  
FACTOR HAVING  
ANTAGONISTIC PROPERTIES

Examiner: SAOUD, C.

Art Unit: 1647

NOT ENTERED

RECEIVED

FEB 26 2002

TECH CENTER 1600/2900

## CERTIFICATE OF MAILING

I hereby certify that this correspondence, including  
listed enclosures, is being deposited with the United  
States Postal Service as First Class Mail in an envelope  
addressed to: Commissioner for Patents, Box AF,  
Washington, D.C. 20231 on January 9, 2002.

Signed:

Wendy Wilson

## RESPONSE

Commissioner for Patents  
Box AF  
Washington, D.C. 20231

Sir:

This is in response to the Office Action mailed July 9, 2001 (Paper No. 28). A Notice of Appeal was filed December 10, 2001, together with a Petition for Extension of Time for two months. Please give favorable consideration to the amendments and remarks herein.

## IN THE CLAIMS:

Please enter the following amended claim set, cancelling without prejudice, disclaimer or admission all previously pending claims not reiterated herein (*i.e.*, Claims 3, 8 and 9).

1. (Four Times Amended) A vascular endothelial cell growth factor (VEGF) antagonist molecule comprising a variant VEGF polypeptide, said variant polypeptide comprising an amino acid modification of at least one cysteine residue at position 51 and/or 60 of the native VEGF, wherein said antagonist molecule is capable of binding to VEGF receptors without significantly inducing a VEGF response, wherein said antagonist molecule is capable of inhibiting a biological activity of a native VEGF protein, wherein said biological activity is induction of a VEGF response.